David S.  Tierney net worth and biography

David Tierney Biography and Net Worth

Director of Zevra Therapeutics
Dr. Tierney joined KemPharm’s board in March 2015. Since February 2020, Dr. Tierney has served as chief executive officer of Pharma Two B, Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease. From September 2019 until January 2020, Dr. Tierney served as president and chief executive officer of BiopharmX, a dermatology drug development company. From March 2014 until March 2018, Dr. Tierney was president chief executive officer of Icon Bioscience, Inc., a privately held ophthalmology company, which was merged into Psivida, Inc to form Eyepoint Pharmaceuticals. From January 2013 until March 2014, Dr. Tierney was a venture partner at Signet Healthcare Partners, a New York City based life science private equity fund. Dr. Tierney served as president and chief operating officer and as a member of the board of directors of Oceana Therapeutics, Inc., a private specialty pharmaceutical company, from its organization in 2008 through its sale to Salix Pharmaceuticals, Ltd. in December 2011. Dr. Tierney served as the president and chief executive officer and as a member of the board of directors of Valera Pharmaceuticals, Inc., a specialty pharmaceutical company, between August 2000 and April 2007, when Valera completed a merger with lndevus Pharmaceuticals, Inc. From January 2000 to August 2000, Dr. Tierney served as president of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company. From March 1997 to January 2000, Dr. Tierney was senior vice president of drug development at Roberts Pharmaceutical Corporation and from December 1989 to March 1997, Dr. Tierney was employed by Elan Corporation, a pharmaceutical company, in a variety of management positions. Dr. Tierney is also a director of Catalyst Pharmaceuticals, Inc., BiopharmX and Bimeda, Inc., a private global veterinary pharmaceutical company. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland and was subsequently trained in internal medicine.

What is David S. Tierney's net worth?

The estimated net worth of David S. Tierney is at least $0.00 as of December 12th, 2023. Dr. Tierney owns 333,541 shares of Zevra Therapeutics stock worth more than $0 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Tierney may own. Learn More about David S. Tierney's net worth.

How do I contact David S. Tierney?

The corporate mailing address for Dr. Tierney and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on David S. Tierney's contact information.

Has David S. Tierney been buying or selling shares of Zevra Therapeutics?

David S. Tierney has not been actively trading shares of Zevra Therapeutics during the past quarter. Most recently, on Wednesday, May 25th, David S. Tierney bought 2,000 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $4.39 per share, with a total value of $8,780.00. Following the completion of the transaction, the director now directly owns 5,835 shares of the company's stock, valued at $25,615.65. Learn More on David S. Tierney's trading history.

Who are Zevra Therapeutics' active insiders?

Zevra Therapeutics' insider roster includes R. Clifton (CFO), Travis Mickle (CEO), Richard Pascoe (Chairman), and David Tierney (Director). Learn More on Zevra Therapeutics' active insiders.

David S. Tierney Insider Trading History at Zevra Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2022Buy2,000$4.39$8,780.005,835View SEC Filing Icon  
11/30/2021Buy2,000$7.79$15,580.00View SEC Filing Icon  
3/20/2017Buy1,000$4.20$4,200.006,000View SEC Filing Icon  
See Full Table

David S. Tierney Buying and Selling Activity at Zevra Therapeutics

This chart shows David S Tierney's buying and selling at Zevra Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zevra Therapeutics Company Overview

Zevra Therapeutics logo
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $5.51
Low: $4.48
High: $6.27

2 Week Range

Now: N/A

Volume

64,100 shs

Average Volume

189,500 shs

Market Capitalization

$200.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16